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I. Context
Stem cells are undifferentiated cells in the human body able to replenish themselves by dividing or capable
under particular natural or medically-induced circumstances to develop into the more specialized cells
forming bones, nerves, body tissue, brains, muscles and blood. Somatic (“adult”) stem cells can be
extracted from various body parts. Stem cells are interesting to scientists and physicians for three reasons.
First, studying stem cells reveals more about the processes of normal and abnormal cell development,
providing knowledge with potential for treating cancer and birth defects arising from faulty cell division.
Second, stem cells offer the possibility of regenerative therapy for a range of diseases and conditions
because they can develop into any body part. The goal is to develop regeneration in other organs where it
does not occur naturally by using stem cells to develop healthy cells of the affected organ or tissue and
inject those new cells into patients. Third, stem cells can be used in therapeutic cloning to correct lifethreatening genetic defects.1
Stem cell research has provoked considerable ethical concern. Some observers worry that it will lead to
cloning of humans or producing “designer babies” with traits their parents desire by using in vitro
fertilization techniques. While many welcome the prospect of more effective treatments of birth defects or
diseases, using human embryonic stem cells for such treatments or even in scientific research is very
controversial. The embryo must be destroyed to secure its stem cells, and anyone who believes that

1 Good internet sources of basic information on stem cells and stem cell research include www.isscr.org/public produced by the
International Society of Stem Cell Researchers and http://stemcells.nih.gov produced by the US National Institutes of Health.
The US government-run Medline Plus Encyclopedia at http://www.nlm.nih.gov/medlineplus/ency/ has good basic information
about diseases, conditions, and treatments.
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human life begins at the moment sperm fertilizes egg to turn it into an embryo regards destroying embryos
as committing murder.
Stem cells exist in all humans, and can be derived from adults’, umbilical cords (which are discarded after
birth), and embryos. Somatic (“adult”) stem cells were first identified in bone marrow in the 1960s and used
for treatments of leukemia, aplastic anemia, and some immune system deficiencies. Bone marrow
transplants are also used to aid recovery from strong radiation treatments or chemotherapy. Embryonic
stem cells were first derived from mouse embryos in 1981, and from human embryos in 1998. A process
for “reprogramming” specialized adult cells to resemble stem cells was developed with mice during 2006
and extended to humans in 2007. The resulting induced pluripotent stem cells (iPCSs) have inspired
considerable interest because they would not inspire the same ethical concerns inspired by derivation of
embryonic stem cells. However, the methods for “reprogramming” are not yet routine and, because they
involve use of viruses, may pose significant hazards. Various types of somatic stem cells have been used
in certain medical treatments, and may have the advantage of being less likely to trigger rejection since
they are grown from the patient to be cured, but they are shorter-lived and more difficult to increase through
cell culture techniques than the embryonic stem cells derived from blastocysts (embryos in their 3rd through
5th day of development after fertilization).
Excitement generated by the first acquisition of human embryonic stem cells in 1998 spread around the
world. In South Korea, where scientists and the government had been attuned to advances in genetics,
bioscience, and biotechnology since the mid-1980s, there was strong interest in taking up the new
possibilities. Four years earlier the South Korean government had adopted an ambitious Plan 2000
intended to make South Korea one of the leading sites of bioscience and biotechnology research in the
world. In 1990, it provided its national Genetics Research Institute with ample facilities in the new Taedok
Science town just outside Seoul; in 1995 it expanded the Institute and renamed it the Korea Research
Institute for Bioscience and Biotechnology to better reflect its expanded areas of work. After 1998 South
Korean government agencies were eagerly funding research on human embryonic stem cells and on
somatic cell nuclear transfer (removing the nucleus of an unfertilized egg cell, replacing it with material from
the nucleus of a specialized body cell, and stimulating this assembled cell divide), both of which promised
to usher in a new range of medical therapies. In early 2003, the Ministry of Science and Technology
reaffirmed its continuing interest by funding a project on xenotransplantation to be carried out by about 184
researchers in over a dozen Korean universities.2
Koreans became very excited about the therapeutic possibilities of stem cells as scientists suggested that it
would not be long before stem cell-based treatments of various genetic defects and still-incurable diseases
would be developed. Korean business leaders also saw considerable potential for industrial leadership in
the field based on the apparent strength of local research.
Dr. Hwang Woo-suk, a member of the veterinary faculty at Seoul National University, emerged as one of
South Korea’s leading stem cell and cloning researchers in 1999 after claiming to have cloned cows. In
2002-05 he and several teams of collaborators were pursuing research on human and animal cloning and
on embryonic stem cells. The human stem cell research raised three ethical concerns. The first arose
from Hwang’s plan to clone human embryos to provide stem cells from which he hoped to make “tailored”
“Biotech powers Korea,” Korea Herald, 2 October 2003 available via http://www.digitalbio.com/board/kboard.php?board=eng_news&act=view&no=227 (accessed 15 September 2009).
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or “patient-specific” stem cells. Stem cells had already been derived from human embryos – “spares”
remaining in storage at fertility clinics after in vitro fertilization of an egg then implanted into a woman’s
uterus. Even this use of embryos had aroused serious controversies in some countries. Religious
conservatives and philosophers treating embryos as fully human, and therefore, entitled to complete
respect of their human identity, condemned using the “spare” embryos as a source of stem cells. Many
more people were uneasy about the notion of cloning human embryos for any purpose, including the
derivation of stem cells. As Dr. Hwang and his colleagues set to work, 12 countries had already banned all
forms of human cloning3 and other scientists in South Korea criticized Hwang for pressing forward with
embryo cloning when the question of its propriety had not been debated or settled.4 The second ethical
concern arose when other scientists charged in late 2005 that at least two, and possibly as many as five,
papers published by Hwang and collaborators contained fabricated data.5 The third, which is the subject
of this case, arose from questions about how Hwang and his collaborators recruited women to donate eggs
(oocytes) for the research. This controversy involved basic issues about treatment of human research
subjects that had been debated at length in many countries.
Concern about protecting humans, whether patients or healthy persons, from abuse by medical
researchers became acute in the wake of revelations about experiments on prisoners in Nazi concentration
camps. The Nuremberg War Crimes Trials resulted in convictions of several of the participating physicians
of crimes against humanity.6 The detailed revelations of the trial also inspired the earliest internationally
agreed statement of ethics relating to human subjects, the Nuremberg Code of 1947. It set forth the
principles of informed consent, absence of undue influence in securing that consent, humane conditions,
avoidance of unnecessary pain, and clear scientific benefit. Continuing abuses, including the deliberate
infection of unknowing human subjects with serious diseases that had been a central part of the charges
against the Nazi physicians, were known to medical researchers. 7 In 1964 the World Medical Association
adopted the first version of the Declaration of Helsinki outlining ethical standards to guide use of human
subjects in medical research. General public attention was revived in the USA and other countries during
1972-73 by extensive newspaper discussion and Congressional Hearings on the Tuskegee Syphilis Study
(1932-1972). It involved two clear violations of the Nuremberg Code: the African-American males selected
for the study were given incomplete and misleading information about the goals and duration of the
experiment, and were denied adequate treatment for the disease even after highly effective penicillin cures
were developed in 1947 so researchers could continue observing the natural course of the disease.8
3R.M.

Isasi and B.M. Knoppers, National Regulatory Frameworks regarding Human Cloning for Reproductive and
Therapeutic/Research Purposes, August 2005 available at http://www.dnapolicy.org/pdf/cloning.pdf (accessed 14 Sept 2009).
Letter to the editor by Song Sang-yong, President of the Korean Bioethics Association, and response by Hwang Woo-suk and
Moon Shen-yong defending their work as conforming with all requirements of South Korean law in Science 305: 944-945 (13
August 2004).
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Hooper, “Rise and fall of the stem cell king,” New Scientist 188 (No. 2531/2532): 24 December 2005.

George J. Annas and Michael A. Grodin, eds., The Nazi Doctors and the Nuremberg Code: Human Rights in Human
Experimentation. New York: 1992; Paul Hoedeman, Hitler or Hippocrates: Medical Experiments and Euthanasia in the Third
Reich, Ralph de Rijke, trans. Lewes 1991.
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Henry K. Beecher, “Ethics and clinical research,” New England Journal of Medicine 274: 1354-1360 (1966).

8James

H. Jones, Bad Blood: The Tuskegee Syphilis Experiment. New York: The Free Press, 1981.

3

Case Summary
Reports of severe maltreatment of patients in psychiatric hospitals later in the decade kept the issue in
view, with later revelations inspiring the World Medical Association to revise the Helsinki Declaration
several times. In 2002 when Hwang’s research teams first recruited egg donors, the 2000 revision was the
most recent statement. While the Helsinki Declaration was the statement of an international professional
group, similar standards had been incorporated into national law or regulations governing the conduct of
medical research on humans in many countries.
South Korean law did not address the question of permissible and impermissible types of genetic research,
cloning, or stem cell research in 2002, but it did include provisions for protection of human subjects.
Korean universities and research hospitals were required to have an Institutional Review Board and
researchers were required to submit their plans for all research using human subjects, a description of how
they will select human subjects, and copies of the consent forms they intend to use for the IRB’s approval
before starting their experiments. South Korean law also required that an IRB include non-researchers,
specifically “more than one attorney or religious representative, not from the fields of medicine, dentistry,
oriental medicine, pharmacy, or nursing sciences.”9
Paragraph 1 of the Helsinki Declaration specifies that, “medical research involving human subjects includes
research on identifiable human material and identifiable data.” Thus its guidance applies to any form of
stem cell research that begins with securing stem cells from human body parts or embryos. The
Nuremberg Principles and the Helsinki Declaration also cover the process of securing eggs and sperm
needed to produce embryos since these require human participants. The stimulation of erection and
ejaculation needed to secure sperm do not require any drugs or surgery; egg donation involves hormone
injections and a surgical procedure, so most of the attention devoted to questions of protecting donors has
focused on the women providing eggs.
The basic surgery for egg donation is minor, and can be performed in a clinic. The process begins with one
or more injections of hormones that cause ovaries to “superovulate”—to produce 12-20 eggs per menstrual
cycle rather than the usual single egg. The eggs are then gathered from the ovary by follicular aspiration,
in which a long needle is passed through the vagina into each ovary and eggs removed from the follicles by
a suction device connected to the needle. All women who undergo follicular aspiration are given pain
killers during the procedure and will feel cramping for up to a day afterward. The hormone injections can
cause ovarian hyperstimulation syndrome (OHSS), and in the USA some 10% of women undergoing
follicular aspiration for in vitro fertilization treatments experienced OHSS afterward. The risk is greater for
women who are under 35 years old, have high estrogen levels, or have polycystic ovarian syndrome (cysts
blocking follicles in the ovaries). The risk is also increased for women receiving injections of human
chorionic gonadotropin (hCG) to help trigger ovulation, particularly if they receive more than one dose of
hCG after ovulation. Risk is much lower among women given fertility drugs taken by mouth. Mild cases of
OHSS produce abdominal bloat and discomfort, and water retention weight gain of about 5 pounds; these
symptoms correct themselves in a few days with rest, ample fluids, and avoidance of stressful activity.
Severe cases of OHSS produce weight gain of more than 10 pounds, severe abdominal pain and swelling,
decreased urination, and shortness of breath. Such cases are usually treated in hospital where the
woman’s condition can be monitored as excess are removed from abdominal and chest areas and
intravenous provision of nutritional fluids restores electrolyte balance. Severe OHSS can lead to life9O.J. Kim, B.J. Park, D.R. Sohn, S.M. Lee, and S.G. Shin, ”Current status of the institutional review boards in Korea,” Journal of
Korean Medical Science 18 (1): 3-10 (2003).
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threatening complications: blood clots, kidney failure, electrolyte imbalance, or massive fluid buildup in
chest and abdomen.10 It can also cause infertility.
The ethical standards for human subjects research most relevant to donors are the requirements for
voluntary informed consent to the medical procedures involved, high standards of researcher competence,
and provision of needed treatment for subjects experiencing ill effects.
Both the Nuremberg Code and the Helsinki Declaration gave detailed definitions of the required consent to
participate. Article 1 of the Nuremberg Code specified that:
… the person involved should have legal capacity to give consent; should be so situated as to be
able to exercise free power of choice, without the intervention of any element of force, fraud,
deceit, duress, over-reaching, or other ulterior form of constraint or coercion; and should have
sufficient knowledge and comprehension of the elements of the subject matter involved as to
enable him to make an understanding and enlightened decision. This latter element requires that
before the acceptance of an affirmative decision by the experimental subject there should be made
known to him the nature, duration, and purpose of the experiment; the method and means by
which it is to be conducted; all inconveniences and hazards reasonably to be expected; and the
effects upon his health or person which may possibly come from his participation in the experiment.
The Helsinki Declaration adopts similar standards. Paragraph 22 of the 2000 version read:
In any research on human beings, each potential subject must be adequately informed of the aims,
methods, sources of funding, any possible conflicts of interest, institutional affiliations of the
researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail.
The subject should be informed of the right to abstain from participation in the study or to withdraw
consent at any time without reprisal. After ensuring that the subject has understood the
information, the physician should then obtain the subject’s freely- given informed consent,
preferably in writing. If the consent cannot be obtained in writing, the non-written consent must be
formally documented and witnessed.
Paragraph 23 added:
When obtaining informed consent for the research project, the physician should be particularly
cautious if the subject is in a dependent relationship with the physician or may consent under
duress. In that case the informed consent should be obtained by a well-informed physician who is
not engaged in the investigation and who is completely independent of this relationship.11

Information on OHHS from the US National Institutes of Health MedlinePlus Medical Encyclopedia at
http://www.nlm.nih.gov/medlineplus/ency/article/007294.htm (accessed 21 July 2009). The 10% incidence figure was calculated
in 2007.
10

11 Declaration of Helsinki, 2000, available at http://www.mch.org.tw/top_2/IRBWORD/Declaration%20of%20Helsinki.pdf (The
World Medical Association’s site at www.wmanet.org/e/policy now carries only the 2008 version).
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Another statement of similar principles widely followed in Korea appears in the International Conference on
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines
for Good Clinical Practice (ICH-GCP) adopted in 1997. The conference is a body consisting of drug
regulatory agencies in the EU, Japan, and the USA plus pharmaceutical industry representatives; the GCP
are jointly-established standards for clinical trials. Following the guidelines means the results data will be
accepted by EU, Japanese, and US authorities. As pharmaceutical firms began pursuing trials in more
countries, cooperating investigators elsewhere were brought within the guidelines, and they diffused
through researcher communities in other parts of the world.
When the South Korean stem cell research projects began in 2002, scientists around the world generally
agreed that undergraduate and graduate students, junior members of research teams, and other
employees over whom researchers have supervisory authority should not be used as donors. Art Calpan,
Head of the University of Pennsylvania Center for Bioethics, commented as the scandal broke in May 2004
that using students or junior members of research teams is bad because “it could certainly look like
coercion was involved”12 and other scientists expressed similar views. There was no global consensus on
whether egg donors could be paid. Some countries prohibited payment; others allowed small payments as
compensation for time or travel expenses; others allowed direct payment.
In 2002-03, South Korean law about medical research had several gaps. The Korean Food and Drug
Administration oversaw the use of human subjects in commercial research projects, including clinical trials,
but its authority did not extend to scientific research. Supervision of scientific research was left to the
Institutional Review Boards of individual universities or hospitals. The typical IRB did require human
subjects to give voluntary, written consent to participate. Korean regulations banned donations from junior
members of research teams,13 but did not specifically ban paying donors. Korean participants in a
UNESCO-sponsored workshop on bioethics held in Seoul in mid-November 2004 noted that “There are
currently no special guidelines or regulations on human research other than within the medical field, and
this deficiency needs to be addressed. For international research, Korean medical scientists are required
to observe ICH-GCP.”14
II. The Controversy
In 2002 when his team began their effort to develop patient-specific stem cell lines by extracting stem cells
from cloned embryos, Dr. Hwang Woo-suk was one of South Korea’s leading stem cell researchers. He
already had a record of considerable research accomplishment, was skilled at organizing teams for large
projects, and had sufficient international reputation to recruit foreign collaborators. He was a veterinarian,
on the Veterinary Faculty at Seoul National University, and therefore not qualified to perform medical
procedures on humans. Acquisition of human oocytes for his research was accomplished by various
12

David Cyranoski, “Korea’s stem-cell stars dogged by suspicion of ethical breach.” Nature 429 p. 3 (6 May 2004).

Noted in Kristen Philipkoski, “Jabs, honors for stem-cell expert,” Wired Magazine 16 Nov. 2005. Available from
http://www.wired.com/medtech/health/news/2005/11/69596 (accessed 20 July 2009).
13

Quoted from the summary of proceedings of the UNESCO-Korean National Commission for UNESCO workshop on “Ethics
around the World – Seoul: Towards a Declaration on Universal Norms on Bioethics” 16 November 2006 available at
http://unesdoc.unesco.org/images/0014/001495/149562e.pdf (accessed 16 July 2009).
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physician collaborators at Hanyang University Hospital, MizMedi Women’s Hospital, Hanna Women’s Clinic
and Chiel General Hospital in Seoul.
Collaborators at Hanyang University Hospital submitted plans for the experiments and for procurement of
oocytes to its Institutional review Board, which approved them. Enough oocytes were acquired to begin the
cloning and stem cell extraction in late 2002- early 2003. Meanwhile, Hwang and his collaborators also
worked on other projects, including efforts to clone animals. Results of the experiments were published in
leading scientific journals. Science published his team’s claim to have cloned human embryos in August
200415 and to have derived patient-specific stem cells in May 2005.16 Nature published his team’s claim to
have cloned a dog in August 2005.17
Though online supplementary material published with the 2004 paper in Science indicated that volunteers
were not paid and had provided informed consent on forms detailing how the eggs would be used, rumors
that two female members of Hwang’s research team had donated eggs and that other donors had been
paid began to circulate in late 2003. Science journalists on Nature’s staff made some inquiries and
published a short comment about the allegations in May 2004.18 Hwang denied the allegations and was
supported in his denial by members of the Hanyang University Hospital IRB. However, the controversy did
not go away. In late May, Members of the South Korean Bioethics Association called on Hwang to answer
continuing questions about the egg donors and the sources of his research funding. Nature printed another
report about the controversy in its June 3rd issue.19
Public support for Hwang’s research remained high. Publication of the patient-specific stem cell paper in
Science had triggered a threefold rise in prices of South Korean biotech stocks. In late June, the South
Korean Ministry of Science and Technology honored Hwang with the new title of Supreme Scientist and
awarded him the equivalent of US$15 million in research support. An internet “I love Hwang Woo-suk” fan
club also appeared. Excitement continued as MgenBio, a Seoul National University-affiliated venture firm
set up by Hwang and others, announced successful cloning of transgenic pigs expressing human leukocyte
antigen (HLA)-G, which is thought to improve immune tolerance of humans to transplanted pig tissues. If
the antigen had the expected effects, this would permit using pig organs, cells, or tissues in a range of
disease treatments.20 Korean media reports that the government planned to establish a World Stem Cell
Hub to be a repository of stem cells were confirmed in October when South Korean President Roh Moohyun authorized allocation of government funds for its establishment at Seoul National University and
appointed Hwang as its President. In mid-November, the government indicated that it would provide 11.5
Hwang, W.-S. et al. "Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst". Science 303
(#5664), 1669–1674 (2004).

15

16 Hwang, W.-S. et al. "Patient-specific embryonic stem cells derived from human SCNT blastocysts" Science 308 (# ), 1777–
1783 (2005).
17

.

Hwang, W.-S. et al., "Dogs cloned from adult somatic cells". Nature 436 (#7051): 641

18Comment,
19David

“Ethics of therapeutic cloning,” Nature 429 (# 6987): 1 (6 May 2004).

Cryanoski, “Korean bioethicists call for inquiry into stem cell work” Nature 429 (#6991): 490 (3 June 2004).

20 The state of knowledge at the time is summarized in Jeffrey L. Platt, Xenotransplantation: Basic Research and Clinical
Applications. Totawa, NJ Humana Press, 2002.
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billion won ($11 million) for the Hub and make it independent from Seoul National University. Plans also
called for establishment of regional affiliates in cooperation with universities in other countries, and
representatives of the Hub began visiting potential collaborators abroad.
Doubts about the propriety of the oocyte donations continued to swirl, and at about the same time two of
Hwang’s US-based collaborators, Dr.Gerald Schatten of the University of Pittsburgh (USA) and the Pacific
Fertility Clinic in San Francisco California, announced they were suspending their collaborations with
Hwang. Schatten released a statement saying that the decision was based on concerns about the oocyte
donations:
Yesterday information came to my attention suggesting that misrepresentations might have
occurred relating to those oocyte donations. The nature of this information mandates
confidentiality. I have contacted appropriate academic and regulatory agencies regarding this new
information and accordingly have suspended my collaborations with Dr. Hwang.21
This was an issue on which he was very sensitive because earlier in his career he had unknowingly worked
with illegally procured oocytes.22 Commentators soon noted that he was in a good position to know the
details of the Korean situation because one of the junior researchers later revealed as a donor was working
in his lab at the time.23
Comments about the situation from European and US scientists in mid-November concentrated on two
charges: securing egg donations from female researchers within Hwang's laboratory group and incomplete
information about the risks of follicular aspiration. Researcher donation was not allowed in mainstream
laboratories in the United States and elsewhere in the world because of the potential for coercion. USbased commentators also recalled that in California, where in vitro fertilization was widely practiced and
human embryonic stem cell research being advanced under a $3 billion public bond issue, some egg
donors had died after egg extraction procedures.
Plans to establish the regional affiliates (“sub hubs”) soon ran into problems. Efforts to establish a sub hub
In San Francisco were stymied when both the University of California San Francisco (UCSF) and the
California Institute for Regenerative Medicine (the central coordinator of the State-funded stem cell
research effort) declined to participate. Arnold Kriegstein, Head of UCSF’s Institute of Tissue and Stem
Cell Biology told journalists he had met with Hwang’s representatives but decided not to participate owing
to concerns about the vagueness of guidelines regarding egg donor recruitment and tracking of research
materials transferred between labs. British scientists expressed similar concerns as efforts to establish a
sub hub at the University of Edinburgh also came to nothing.24

21 Quoted in David Glenn, "In South Korea, ethics questions prompt a stem-cell pioneer to resign a top post." The Chronicle of

Higher Education 52 .16 (Dec 9, 2005)
22Lila

Guterman, “A Silent Scientist under Fire” Chronicle of Higher Education, 52.22 (3 Feb 2006), pp. A15-A19

23[note
24

missing at this time]

C. Holden “Stem-cell research: Korean cloner admits lying” Science 310 (#5753): 1402-1403 (2 December 2005).
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The controversy intensified in South Korea and elsewhere on November 21st when Dr. Roh Sung-il, Head
of the fertility clinic at MizMedi Women’s Hospital where many of the oocytes used by Hwang’s team were
donated, held a news conference and told the assembled journalists that in 2002 he had paid some 20
women the equivalent of US$1,400 each for donating the eggs used in the research for Hwang's 2004
embryo cloning paper. Roh added that payment had become unnecessary later because women were
willing to donate eggs without compensation after Hwang's work became well-known. He also insisted that
Hwang did not know about the early payments. Roh’s claim that payments were unneeded later appeared
to be confirmed by news that the non-profit foundation established by Hwang’s supporters the same day to
secure egg donations had been contacted by 800 women volunteering to become donors before the end of
the week.
So strong was the support for Hwang that after Munhwa Broadcasting Company showed a segment of its
news program PD Su-Cheop (Producer's Notebook) discussing the egg donation controversy it was
accused of being unpatriotic, several advertisers dropped their ads, demonstrators picketed company
headquarters in Seoul, and the program’s producers of the program were threatened in posts to Internet
chat boards. Many Koreans agreed there had been ethical lapses, but felt the controversy and the
pressure on Hwang reflected efforts to impose Western standards on Korean scientists. Supporters were
also quick to point out that payments to donors were not banned in South Korea in 2002-03. The Bioethics
and Biosafety Act adopted in late 2003 but not scheduled to take effect until January 2005 closed the door
indirectly by providing in Article 13, paragraph 1 that embryos can be produced from sperm and oocytes
only for the purpose of pregnancy and in Article 13, paragraph 3 that “No one shall induce or assist in
providing or utilizing sperm or oocytes for the purpose of receiving financial reward, property, or any other
personal benefits.”25 However, the new law also permitted the practice already adopted in many other
countries of allowing research to be performed with “spare” embryos.
On November 24th Hwang called a press conference to announce his intention to resign as President of the
World Stem Cell Hub. He claimed he had rejected proposals that team members donate eggs while
acknowledged that two members of his team had done so. He said they had gone ahead and donated
under false names, he had found out about the donations later, and lied about the source of eggs to protect
their privacy. To critics pointing out that he should have been aware that having members of the research
team act as donors contravened the Helsinki Declaration, Hwang replied that he was unaware of that
Declaration.
Hwang’s defenders in the government and among the public still felt the charges reflected an unfair
imposition of foreign standards on Korean researchers. Health Ministry official Choi Hee-joo was quoted on
November 24th as saying the women providing eggs for Hwang’s research were motivated by a desire to
serve science, their actions accorded with Asian ethical conceptions, and neither they nor Hwang’s team
should be judged by Western standards.
On November 29th, controversy about the propriety of oocyte donations was swamped by claims that
Hwang’s team had fabricated data in their May 2005 paper claiming to have created patient-specific stem
cell lines. Tipped off, Munhwa Broadcasting raised the charges in another segment of PD Su-Cheop.
25 South Korean Biosafety and Bioethics Act 2005 (Act No. 7150), unofficial English translation by Koo Young-mo and John
McGuire Nov. 2004, available at ruhr-uni-bochum.de/kbe/Bioethics&BiosafetyAct-SouthKorea-vl.0.pdf (accessed 16 July 2009).
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Though this intensified ire against Munhwa, the charges were quickly elaborated by scientists and became
the subject of worldwide discussion in early December.
In mid-December Seoul National University convened a 9-scientist internal review panel to look into all of
the charges against Hwang. Its reports in December and January confirmed the charges that he had faked
data in the stem cell papers. They also confirmed irregularities in procurement of oocyte donations. First,
the review panel concluded that Hwang’s team had used at least 273 eggs to produce embryos, rather than
the 185 they reported in the May 2005 Science paper. It also rejected Hwang's claim that he was unaware
of egg donations by female researchers on his own team after being informed that he had distributed egg
donation consent forms to his researchers and even gave one of them a ride to MizMedi Hospital for the
egg extraction procedure.
In its 2008 report on the controversy, South Korea’s National Bioethics Committee summarized the egg
donations secured by Hwang’s collaborators as follows:
Location
MizMedi Hospital
Hanna Women’s Clinic
MizMedi Hospital
Hanna Women’s Clinic
Hanyang Univ. Hospital
Cheil General Hospital
MizMedi Hospital
Hanyang Univ. Hospital
Hanyang Univ. Hospital

type
paid
in-kind benefit
volunteer
volunteer
volunteer
volunteer
researcher
ovary removal 1
ovary removal 2

women
63
23
14
11
8
1
2
114
72

[ovary removal 1 = data in Ryu Young-june 2004 MA Thesis]
[ovary removal 2 = data from Seoul Prosecutor’s Office for 2002-2003]

donations
75
25
14
12
9
1
2
114
113

eggs acquired
1336
313
182
230
121
8
31
more than 537
not reported

The Committee also noted information about side effects. 17.9% of the donors treated at MizMedi Hospital
suffered OHSS afterward; one paid donor who donated twice needed hospitalization for OHSS both times.
2 of the 11 volunteer donors at Hanna Women’s Clinic suffered ascites afterward. No cases of side effects
were reported from Hanyang University Hospital or Cheil General Hospital.26
III. Implications
The controversy over methods of recruiting egg donors reflected the combination of global consensus on
some points and continuing disagreement about others. Though there is a long history of selfexperimentation – including use of family members and associates – in medical research, today there is
consensus that students and junior members of research teams should not be used as donors to avoid
even the suggestion of compulsion. There is still no agreement on whether donors may be paid. Article
12(1) of the European Union’s 2004 Tissue and Cells Directive specifies that Member States should
establish systems of voluntary and unpaid tissue and cell donation but may allow “compensation which is
strictly limited to making good the expenses and inconveniences related to the donation” and must define
26

Republic of Korea, National Bioethics Committee, 2008. English-language summary available in Appendix 2.
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the conditions under which compensation will be paid in national law or regulations. The US National
Institutes of Health guidelines also recommend against payments to egg donors, though advertisements
soliciting egg donations to help infertile couples conceive offer significant payments. In June 2009, the
New York State (USA) Stem Cell Board, which oversees the state government’s 11 year, $600 million
dollar program, approved payments of up to $10,000 per donation to overcome the scant supply of suitable
eggs. Even proponents of the measure worried that some women would try to donate multiple times for the
money, and proposed maintaining a general donor register to keep this from happening.27
Hwang’s foreign collaborators were nervous about the egg donor recruitment scandal even before the data
fabrication charges became public or Hwang confessed he was aware at the time that younger female
members of his research team had donated eggs. Hwang’s team could have continued work without the
foreign collaborators, but their concerns certainly contributed to the World Stem Cell Hub’s difficulty finding
foreign institutions willing to host regional affiliates in fall 2005.
The data fabrication scandal was a more significant setback to South Korean aspirations than the egg
donation scandal because the ethical questions involved provoked no disagreement. While a few
commentators felt that data fabrication contributed to discrediting science generally, most agreed that the
scientific requirements for repeatability of results make detection of data fabrication more likely in scientific
work than in business, journalism, or politics. As Rob Carlson put it, “There is no other human institution so
ruthless in chopping out the dead wood. After all, if you are lying or pulling a fast one, the very last thing
you want to do is get a bunch of really smart people trying to catch you out, all of whose professional
standing improves if they do.” This protective mechanism is very strong in areas of well-established
science. In the more rapidly changing, and more exciting, areas of frontier science, where results have not
yet been tested by others, competition is sharper and there is more room for cheating. Yet, even there, as
the Hwang case shows, others’ inability to replicate results will inspire doubts.
Though some observers feared that revelations of Hwang’s data fabrication would discredit science
generally, the effects were confined mainly to stem cell research, and even there they were relatively short
lived because of the multiple methods available for acquiring stem cells. Embryo cloning is very inefficient;
the first successful animal cloning, of Dolly the sheep, occurred after 276 unsuccessful attempts. Hwang’s
data fabrication confirmed other scientists in the view that there were no shortcuts on the horizon, and
promoted efforts to develop other methods of acquiring stem cells. While the World Stem Cell Hub folded,
the Korean Research Institute of Bioscience and Biotechnology (KRIBB) still exists. Its researchers are
active in stem cell and other biotechnology research, and KRIBB maintains collaborations with research
institutions and biotechnology companies around the world. Korean scientists remain active in the field,
and the egg donor controversy led to significant improvement in supervision of human subjects research by
the South Korean Ministry of Health and Institutional Review Boards.
South Korean Legislation, Regulations, and Guidelines in force, 2009

from International Compilation of Human Research Protections 2009 Edition, p. 67.
Compiled by the Office for Human Research Protections, U.S. Department of Health and Human Services available
at http://www.hhs.gov/ohrp/international/HSPCompilation.pdf (accessed 31 July 2009)

27

Katherine Harmon, “Shelling out for eggs,” Scientific American, 301(5) 20-21 (November 2009).
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Case Summary
Drugs
Supervising Agency: Korea Food and Drug Administration (Korean): www.kfda.go.kr/
Legislation: Pharmaceutical Affairs Act (No. 91235) Articles 10 and 31-34 (2008)
Regulations: Enforcement Rule of Pharmaceutical Affairs Act Articles 22, 31-34
Guidelines: 1.) Korean Good Clinical Practice Public Notification of Food and Drug Administration, No.
2007-4 (2007)
2.) Guideline for Investigational New Drug Application: Public Notification No. 2004-51 (2004)
Privacy/Data Protection
Supervising Agency: Ministry of Public Administration and Security: http://www.mopas.go.kr
Legislation: Act on the Protection of Personal Information Maintained by Public Agencies No. 8871 (2008)
Genetic Research
Supervising Agency: Ministry of Health, Welfare, and Family Affairs: http://english.mw.go.kr/
Legislation: Bioethics and Safety Act, Chapters 2, 6, 9, 24, 31, 38, and 41 (2005 and 2008 amendments)
Regulations: Enforcement Decree of Bioethics and Safety Act, Articles 2, 3, 13, 14-21, 27, and 28 (2008)
Guidelines: Guidelines for Research Involving Recombinant DNA Molecules (1997)
Embryos, Stem Cells, and Cloning
Supervising Agency: Ministry of Health, Welfare, and Family Affairs: http://english.mw.go.kr/
Legislation: Bioethics and Safety Act, Articles 2, 18-21, 38, 41, and 45 (2005 and 2008 amendments)
Regulations: 1.) Enforcement Decree of Bioethics and Safety Act, Articles 3, 12, and 19-2 (2008);
2.) Enforcement Regulation of Bioethics and Safety Act, Articles 2, 7, and 13 (2008)
Guidelines: Guideline for Stem Cell Research of Cell by Stem Cell Research Center (2006)
<End>
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